Ovid – $75 Million IPO

Palo Alto – June 12, 2017 – Cooley advised Ovid on its $75 million initial public offering of 5,000,000 shares of common stock.

Ovid, which now trades on The NASDAQ Global Select Market as “OVID,” is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.

This transaction follows a series of life sciences IPOs that Cooley advised on in the first half of the year.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Laura Berezin Partner, Palo Alto
Div Gupta Partner, New York
Robert Phillips Partner, San Francisco
Jaime L. Chase Associate, Washington, DC
Sara Semnani Associate, Los Angeles
Alison Haggerty Associate, New York
Pia Kaur Associate, San Francisco
Jeramie Perez Senior Paralegal, Palo Alto
Jason Minio Senior Paralegal, Boston
Natasha Leskovsek Partner, Washington, DC
Phil Mitchell Partner, New York
Ivor Elrifi Partner, New York
Heidi A. Erlacher Partner in Charge - Boston
David Walsh Partner, Reston
Keith Ranta Special Counsel, Washington, DC
Mary Maher Lewis Associate, Reston
Mike Faber Senior Counsel, San Francisco
Francis Wheeler Partner, Colorado